CTOS IS TEN YEARS OLD SARC IS TWO YEARS OLD

1. CTOS IS TEN YEARS OLDSARC IS TWO YEARS OLD Happy Birthday, CTOS, SARC

2. Friend of SARCAllan Van Oosterom, M.D. Ph.D.

3. And they call us the killer B’s?

4. EORTC + SARC

5. SARCMission and Vision • Collaborate to design clinical trials • Further the knowledge regarding diagnosis and treatment of sarcoma • Provide information to physicians, patients and families • Utilize state of the art statistical design Engage all appropriate and necessary resources to cure and prevent sarcomas

6. SARC Statisticians D. Berry P. Thall SARC CTOS Operations L. Baker D. Reinke Institution – Multiple members of CTOS Board of Directors – Majority from CTOS

7. Building Effective Collaborations Through SARC International Sarcoma ResearchGroups Statisticians D. Berry P. Thall SARC CTOS Operations L. Baker D. Reinke US Govt Research Mechanisms Institution – Multiple members of CTOS Board of Directors – Majority from CTOS

8. SARC Executive Committee • L. Baker • B. Benjamin • B. Maki • G. Demetri • L. Helman (consultant)

9. SARC Board of Directors • Executive committee members • Charles Nearburg- Dallas • David Marsh- New York • Deborah Buks- Houston • Tim McCormick-Detroit • Piero Picci, MD-Rizzoli Institute • Frits van Coevorden, MD-Netherlands Ca Inst • Ad hoc • Peter Thall (Stats) • Denise Reinke (Op office)

10. David Marsh writer radio personality SARC board member

11. James Butrynski, MD University of Washington Sant Chawla, MD Century City Hospital Arthur Staddon, MD Pennsylvania Oncology Martin Blackstein, MD Mt. Sinai, Toronto John Murren, MD Yale University Amir Shahlaee, MD University of Florida William Tap MD UCLA* Dennis Priebat, MD Washington Cancer Institute* -Robert Benjamin, MD MDAnderson Cancer Center* -Robert Maki, MD, PhD MSKCC* -Scott Schuetze, MD, PhD University of Michigan* -Lee Helman, MD NCI-Pediatric Branch* -Gina D’Amato, MD Moffitt Cancer Center -Michael Fanucchi, MD Emory -George Demetri, MD Dana-Farber/Harvard * -David Harmon, MD MGH/Harvard * -Scott Okuno, MD Mayo Clinic SARC Participants

12. Potential New Participants • Chris Ryan, MD • Oregon Health Science • Meg Von Mehren, MD • Fox Chase Cancer Center • Kenneth Hande, MD • Vanderbilt Ingram Cancer Center • INTERNATIONAL ALLIANCES • Piero Picci, MD • Rizzoli Institute • Ian Judson, MD • Royal Marsden Hospital • Peter Hohenberger, MD • University of Heidelberg

13. SARC survey • New patient annually • 4814 • Patients treated on protocol • 1790 • Patients treated on SARC protocols • 353

14. SARC survey • 1790 accruals at SARC sites • 195 NCI (18 studies) • 353 SARC (3 studies) • 1242 pharma • SARC partnering with pharma • Investigator initiated studies • sponsored trials

15. Protocols in Development • Dasatinib • sarcoma • Dasatinib • GIST • AMG 706 • Sarcoma • GIST • Perfosine • chondrosarcoma and ASPS

16. What Makes SARC Special? • Patients • Expertise • Commitment • The same things that make most CTOS members and institutions special!

18. THE SARC FUTURE • Combined studies with EORTC • SARC fall meeting part of CTOS • FY2006 Energy Bill • SARC DoD grant for MPNST • SARC Website • NCCN guidelines • Sarcoma trials

19. SARC and Developmental Therapeutics • Sarcoma is recognized as an important model for drug discovery and development • Expanding the preclinical collaborations through SARC • Peter Houghton is interested in STS modeling • Rich Gorlick is interested in bone sarcoma modeling • Chand Khanna has developed a dog coop group to evaluate treatment of dogs with sarcomas • SARC centers can provide access to broader range of relevant tumor tissues through collaboration

20. SARC and Developmental Therapeutics • Phase I investigators to test promising new agents in relevant sarcomas • Anthony Tolcher will collaborate • Developmental Therapy Steering Committee organized • George Demetri-chair

21. Chawla-RosenfeldDevelopment Therapeutic Symposia Eugene and Maxine Rosenfeld Sant Chawla, MD